Drug intelligence / Profile preview

ESO-101

Development stage: Phase 2
Lead developer: EsoCap
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration: Topical

Overview

ESO-101 is a novel small molecule developed by EsoCap AG, a Swiss biotech company. It is a topical formulation of mometasone furoate delivered via a unique mucoadhesive film, primarily intended for the treatment of esophageal diseases. AstraZeneca acquired EsoBiotec (which developed ESO-101) in Q1 2025 to expand its oncology portfolio, indicating a potential broader application or a specific oncology indication for ESO-101. It is currently in Phase 2 clinical trials for eosinophilic esophagitis (EoE) and Phase 1 for esophageal cancer.

Brand names: ESO-101ESO101ESO 101
Other names: EsoCap mometasone furoate mucoadhesive film (descriptive, not official)

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on ESO-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ESO-101.

Explore the full profile